ACA Form 144 Filed for 4,000 Common Shares; Acquired via PSU Vesting

Rhea-AI Filing Summary

Arcosa, Inc. (ACA) submitted a Form 144 proposing the sale of 4,000 common shares through Merrill Lynch on the NYSE, with an aggregate market value of $394,080 and an approximate sale date of 08/12/2025. The filing shows the shares were acquired on 05/15/2024 as the vesting of performance stock units issued under an effective Form S-8, with 7,342 units noted as acquired that date. The document lists 49,044,906 shares outstanding and reports no sales by the seller in the past three months. The broker is identified as Merrill Lynch, Pierce, Fenner & Smith, Inc., 5910 N Central Expressway, Suite 2000, Dallas, TX 75206. Several administrative fields in the extracted content, such as filer CIK, issuer address details, and the signature/date of notice, are not provided in the supplied text. The filer makes the standard representation that they are not aware of any undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider/beneficial holder sale notice for 4,000 shares; immaterial relative to total shares outstanding.

The Form 144 is a procedural notice indicating a proposed sale of 4,000 common shares valued at $394,080 through a national broker on 08/12/2025. The underlying shares originated from PSU vesting on 05/15/2024 under an effective Form S-8. With 49,044,906 shares outstanding, the proposed sale represents a de minimis portion of the float and carries no disclosed recent sales in the prior three months. Absent further context on the seller's identity or larger scheduled disposals, this filing is a routine liquidity event rather than a material corporate development.

Corporate Governance Expert

TL;DR: Filing follows standard disclosure practices for vested equity; missing administrative details limit traceability.

The notice documents the sale channel, acquisition source (vesting of PSUs), and amount to be sold, which aligns with common post-vesting dispositions. However, key administrative elements in the provided extract—such as filer CIK and the signature/date—are not included, reducing the filing's traceability from the supplied text alone. The inclusion of the attestation regarding undisclosed material adverse information is standard. From a governance perspective, the record shows compliance with Form 144 content requirements in substance, though the extracted copy appears partially incomplete.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MERRILL LYNCH, PIERCE, FENNER & SMITH, INC. 5910 N CENTRAL EXPRESSWAY SUITE 2000 DALLAS TX 75206	4000	394080.00	49044906	08/12/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	05/15/2024	VESTING OF PSU ISSUED UNDER AN EFFECTIVE FORM S-8	ACA			7342	05/15/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Arcosa's (ACA) Form 144 disclose?

It discloses a proposed sale of 4,000 common shares through Merrill Lynch on the NYSE with an aggregate market value of $394,080 and an approximate sale date of 08/12/2025.

How were the shares being sold acquired according to the filing?

The shares were acquired on 05/15/2024 as the vesting of performance stock units issued under an effective Form S-8; 7,342 units were reported as acquired on that date.

Does the filing show any sales of Arcosa (ACA) securities in the past three months?

No. The filing states "Nothing to Report" under securities sold during the past three months.

Who is the broker handling the proposed sale?

Merrill Lynch, Pierce, Fenner & Smith, Inc. located at 5910 N Central Expressway, Suite 2000, Dallas, TX 75206.

What outstanding share count does the filing show?

The filing lists 49,044,906 shares outstanding for the issuer.